"10.1371_journal.pone.0031046","plos one","2012-02-27T00:00:00Z","John H Sampson; Robert J Schmittling; Gary E Archer; Kendra L Congdon; Smita K Nair; Elizabeth A Reap; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; April Coan; Roger E McLendon; David A Reardon; James J Vredenburgh; Darell D Bigner; Duane A Mitchell","Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, United States of America; Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America","Conceived and designed the experiments: JHS DAM GEA RJS. Performed the experiments: JHS DAM RJS GEA AD AHF HSF REM DAR JJV. Analyzed the data: JHS DAM RJS GEA SKN EAR JEH AC KLC. Contributed reagents/materials/analysis tools: JHS DDB DAM. Wrote the paper: JHS KLC JEH AC.","Consultant or Advisory Role: JHS, Celldex Therapeutics (C); DDB, Celldex Therapeutics (C) Honoraria: JHS, Celldex Therapeutics; DDB, Celldex Therapeutics Research Funding: JHS. The designation (C) indicates a compensated position. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials. CDX-110 is a Celldex product. There are no patents, products in development or other marketed products to declare.","2012","02","John H Sampson","JHS",16,TRUE,4,10,9,4,TRUE,TRUE,FALSE,0,NA,FALSE
